MARKET

MIST

MIST

Milestone Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.90
-0.98
-11.04%
After Hours: 7.85 -0.05 -0.63% 17:22 09/21 EDT
OPEN
8.50
PREV CLOSE
8.88
HIGH
8.62
LOW
7.77
VOLUME
333.16K
TURNOVER
--
52 WEEK HIGH
23.25
52 WEEK LOW
1.690
MARKET CAP
195.18M
P/E (TTM)
-3.3682
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N., Sept.
CNW Group · 09/08 12:00
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 11:29
Milestone Pharmaceuticals Q2 EPS $(0.53) Up From $(1.04) YoY
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.53) per share. This is a 49.04 percent increase over losses of $(1.04) per share from the same period last year.
Benzinga · 08/12 11:03
Why Earnings Season Could Be Great for Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals (MIST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 08/10 11:47
Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the
PR Newswire · 08/06 11:00
Oppenheimer: These 3 “Strong Buy” Stocks Have Over 50% Upside Potential
Despite COVID-19’s devastating impact on the economy, Oppenheimer’s Chief Investment Strategist John Stoltzfus remains overweight on U.S. equities, and is more bullish on cyclical sectors versus defensive sectors. As for the legitimate concerns about the virus
TipRanks · 07/31 16:34
Milestone Pharmaceuticals (MIST) Hits a Couple Milestones After FDA Meeting; Top Analyst Cheers
Tiny biopharmaceutical company Milestone Pharmaceuticals (MIST) had a big day Thursday, first announcing the completion of one study (NODE-301) and the continuation of a second (NODE-301B, now to be renamed the "RAPID study"), that will, together, support a fu
TipRanks · 07/24 22:17
Juggling Risk And Reward In A Raucous Market
It’s been another week of solid results in a choppy market. As with last week, I’m green on all five days with roughly $180,000 in gross profit. Nevertheless, there were quite a few points where I had to reclaim some lost ground after a chart just broke down.
Benzinga · 07/24 18:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MIST stock price target is 13.25 with a high estimate of 18.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 11.99M
% Owned: 48.53%
Shares Outstanding: 24.71M
TypeInstitutionsShares
Increased
3
645.99K
New
17
-94.68K
Decreased
1
6.90K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average MIST stock price target is 13.25 with a high estimate of 18.00 and a low estimate of 8.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MIST
Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is its short-acting calcium channel blocker. It is developing Etripamil as a nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT), as they occur. It is also focused on developing treatments for other indications, such as Atrial Fibrillation and Angina. Etripamil is in Phase-III development for PSVT.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Milestone Pharmaceuticals Inc stock information, including NASDAQ:MIST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MIST stock methods without spending real money on the virtual paper trading platform.